Breaking News
March 22, 2018 - Researchers explain link between 2 key Alzheimer’s proteins
March 22, 2018 - Patients on replacement therapy with thyroid hormone may have more comorbidities
March 22, 2018 - Higher online patient ratings linked to urologists who saw fewer Medicare patients
March 22, 2018 - FDA Approves Ilumya (tildrakizumab-asmn) for the Treatment of Moderate-to-Severe Plaque Psoriasis
March 22, 2018 - Beer Raises Heart Rate; KardiaBand Hyperkalemia Test; CHD Clinics
March 22, 2018 - A retinal implant that is more effective against blindness
March 22, 2018 - New system based on artificial intelligence provides reliable detection of breast cancer
March 22, 2018 - Research offers new understanding about cause of Parkinson’s disease
March 22, 2018 - HORIBA’s Microsemi CRP analyzer improves quality of care in emergency pediatric units, study shows
March 22, 2018 - Range of Vaginal Dryness Products Can Help Postmenopausal Women: Study
March 22, 2018 - Higher Dose Tx Deemed Safe in Pulmonary TB
March 22, 2018 - Discovery of new ALS gene points to cytoskeleton as potential target for drug development
March 22, 2018 - Diet soda associated with higher odds of diabetic retinopathy
March 22, 2018 - LSD reduces ‘sense of self’
March 22, 2018 - Vitamin D deficiency linked to metabolic syndrome in postmenopausal women
March 22, 2018 - Changes in the intestines may be responsible for reversal of diabetes after bariatric surgery
March 22, 2018 - iPads and Cancer; Clot Retrieval and Stroke: It’s PodMed Double T!
March 22, 2018 - Premature births linked to changes in mother’s bacteria
March 22, 2018 - Brain SPECT scans predict treatment outcomes in patients with depression
March 21, 2018 - Researchers succeed in integrating artificial organelles into cells of living organism
March 21, 2018 - Researchers discover ‘missing mutation’ in severe infant epilepsy
March 21, 2018 - Researchers develop statistics-based computational scheme to zoom in on brain function
March 21, 2018 - Verge joins Genomics England’s Discovery Forum industry partnership
March 21, 2018 - Trovagene Announces First Patient Successfully Completes Cycle 1 of Treatment with PCM-075 in Combination with Low Dose Cytarabine (LDAC) in AML Trial
March 21, 2018 - Congenital Cardiac Cath Tx Often Strays from Guidelines
March 21, 2018 - Marked increase in cardiovascular risk factors in women after preeclampsia
March 21, 2018 - New app may help predict, track manic and depressive episodes in bipolar patients
March 21, 2018 - Discovery of genes could lead to development of novel therapies for EBV-related cancers
March 21, 2018 - High-fat, high-cholesterol diet depletes ranks of artery-protecting immune cells
March 21, 2018 - Research misconduct allegations shadow likely CDC appointee
March 21, 2018 - Most Breast Ca Patients Fail to Get Genetic Counseling
March 21, 2018 - Lopsided ear function can lead to lopsided brain development
March 21, 2018 - Acupuncture helps manage menopausal symptoms, review finds
March 21, 2018 - Motor skill training may contribute to reading skills in obese children
March 21, 2018 - Poor dental health may be related to increased diabetes risk
March 21, 2018 - Chronic opioid users at increased risk of complications after spinal fusion surgery
March 21, 2018 - Study uncovers potential therapeutic target against large family of parasites
March 21, 2018 - NSAID use linked to increased risk of atrial fibrillation
March 21, 2018 - Scientists develop brain “stethoscope” that can detect silent seizures
March 21, 2018 - New method predicts effects of global warming on disease
March 21, 2018 - Insurance Company Hurdles Burden Doctors, May Harm Patients
March 21, 2018 - Renal Transplant from HCV-Positive Donors Feasible
March 21, 2018 - Myelodysplastic syndrome: MedlinePlus Medical Encyclopedia
March 21, 2018 - Research reveals brain mechanism involved in language learning
March 21, 2018 - Many parents still hesitate to try early peanut introduction, survey finds
March 21, 2018 - Audiologist urges tinnitus sufferers facing ‘revolving door healthcare’ to seek support
March 21, 2018 - Study reveals impact of prostate cancer on wives and partners of sufferers
March 21, 2018 - ‘Almost a Miracle Drug’: What We Heard This Week
March 21, 2018 - Study shows NIH spent >$100 billion on basic science for new medicines
March 21, 2018 - Columbia researchers identify nerve cells that drive fruit fly’s escape behavior
March 21, 2018 - Sartorius Stedim Biotech selected by ABL Europe to supply single-use process technologies
March 21, 2018 - Increase in coffee consumption may help battle against colon cancer
March 21, 2018 - Hydrogel may accelerate healing of diabetic ulcers
March 21, 2018 - Dermira’s Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpoints
March 21, 2018 - DePuy Synthes introduces ACTIS Total Hip System for improving initial implant stability
March 21, 2018 - ‘Oh, It Was Nothing’
March 21, 2018 - Herbal drug kratom linked to salmonella illnesses, CDC says
March 21, 2018 - New optical point-of-care device could enhance screening for thyroid nodules
March 21, 2018 - FDA Expands Approval of Adcetris (brentuximab vedotin) for First-Line Treatment of Stage III or IV Classical Hodgkin Lymphoma in Combination with Chemotherapy
March 21, 2018 - Eosinophilic Esophagitis: Late Manifestation of Allergic March
March 21, 2018 - Signaling pathway involving the Golgi apparatus identified in cells with Huntington’s disease
March 21, 2018 - Quintupling inhaled steroid doses may not benefit children with asthma
March 21, 2018 - Study shows clear connection between cardiovascular fitness in middle age and dementia risk
March 21, 2018 - Premature babies have higher risks of health complications in Bangladesh
March 21, 2018 - Child’s temperament and parenting influence weight gain in babies
March 21, 2018 - Researchers find the heart to be capable of arrhythmia termination after local gene therapy
March 21, 2018 - Inhealthcare to provide digital infrastructure for NHS to help protect people from falls
March 21, 2018 - Flu Season Finally Slowing Down
March 21, 2018 - Mixed Results for Shorter DAPT in ACS Patients
March 21, 2018 - Scientists discover fish scale-derived collagen effective for healing wounds
March 21, 2018 - Genomics England announces new partnership to improve efficiency of next-generation sequencing analysis
March 21, 2018 - Adjuvant AC chemotherapy found to be effective in treating HRD-positive breast cancer patients
March 21, 2018 - Researchers identify new treatment targets for lung diseases using big data
March 21, 2018 - Kids see more women in science than five decades ago
March 21, 2018 - Research shows link between chronic fatigue syndrome and lower thyroid hormone levels
March 21, 2018 - Alzheimer’s disease on the rise
March 21, 2018 - Two Agents Equal as Pretreatment for Adrenal Tumor Surgery
March 21, 2018 - ‘Icebreaker’ protein opens genome for T cell development, researchers find
March 21, 2018 - Women in medicine shout #Metoo about sexual harassment at work
March 21, 2018 - Mother’s pre-pregnancy waist size may be linked to child’s autism risk
Oral Insulin No Help for T1D Delay or Prevention

Oral Insulin No Help for T1D Delay or Prevention

image_pdfDownload PDFimage_print

Action Points

  • Oral insulin capsules may not be an effective method for preventing type 1 diabetes in relatives of those with type 1 diabetes.
  • Note that there were no serious adverse events, such as severe hypoglycemic events reported during the trial.

Oral insulin capsules may not be an effective method for preventing type 1 diabetes, according to Diabetes TrialNet researchers.

Oral insulin treatment in relatives of those with type 1 diabetes who were positive for at least two autoantibodies did not have a significant effect on time to diabetes compared with placebo (28.5% insulin group versus 33% placebo, HR 0.87, 95% CI 0.0-1.2, P=0.21), reported Jeffrey P. Krischer, PhD, of the University of South Florida College of Medicine in Tampa, and colleagues in the Type 1 Diabetes TrialNet Oral Insulin Study Group, in the Journal of the American Medical Association.

“We now know that we can identify people long before they have clinical type 1 diabetes [T1D]. Indeed, we now consider that having two or more islet autoantibodies is an early stage of type 1 diabetes. Our aim is now to find therapies that can delay or prevent disease progression from early stages to clinically apparent disease,” explained Carla Greenbaum, MD, director of the Diabetes Program at Benaroya Research Institute in Seattle, Washington, to MedPage Today.

“Oral insulin was first tested as part of the Diabetes Prevention Trial (DPT-1), which started in 1994. In that study, a retrospective analysis suggested that those with higher levels of insulin antibodies and thus potentially a more rapid rate of progression to clinical T1D had a benefit [from] oral insulin. These findings led to the launch of the TrialNet Oral Insulin Prevention Study in 2007,” added Greenbaum, who is also chair of Diabetes TrialNet.

The trial included four groups of participants from the TrialNet Natural History Study (now called the TrialNet Pathway to Prevention study), who were all autoantibody-positive relatives of those with type 1 diabetes. The first group — the main focus of the study — included 389 individuals with higher levels of beta cell function. All participants in this group were also positive for microinsulin auto-antibody (mIAA) and either islet cell autoantibodies (ICA) or both glutamic acid decarboxylase (GAD65) antibody and islet antigen 2 (IA-2) autoantibodies.

The participants were randomly assigned to receive a daily 7.5-mg capsule of recombinant human insulin crystals or placebo pills. The groups were followed up every 6 months for a median of 2.7 years.

For the first of the secondary study groups, 55 individuals were included who had the same autoantibody expression as the first group, but had lower levels of beta cell function. This was measured by a first-phase insulin release — marked by adding 1- and 3-minute insulin values form an IV glucose tolerance test — with thresholds lower than 60 μU/mL for those between ages 3 to 7 years, or lower than 100 μU/mL in those age >8 years.

This group experienced a protective effect with oral insulin capsules, marked by a significantly longer time to diabetes in the treatment group versus placebo (HR 0.45, 95% CI 0.0-0.82, P=0.006). After follow-up, only 48.1% of the treatment group progressed to type 1 diabetes compared to 70.3% of placebo.

“It has long been thought that antigen therapy would be most effective earlier in disease. It is somewhat surprising therefore that in both the post-hoc DPT-1 analysis and in TrialNet’s new study, the benefits were seen in groups with potentially more aggressive disease,” Greenbaum noted. “An alternative explanation is that oral insulin is somehow treating an ‘immune flare’ occurring in those most responsive. If true, this may fundamentally change our understanding of mechanisms of disease progression and how we target therapy.”

In a secondary stratum group of 116 individuals who were positive for the mIAA autoantibody and either the GAD or IA-2 autoantibodies. there were no significant differences in the time to diabetes between the groups (HR 1.03, 95% CI 0.0-2.11, P=0.53). Similarly, time to diabetes was not different when they were compared to all groups (HR 0.83, 95% CI 0.0-1.07, P=0.11).

“Since type 1 diabetes is increasingly understood to be a heterogeneous disease it is possible that oral insulin may be helpful in only a subset of people. It is also possible that oral insulin is more helpful at a certain point in time, when insulin-producing cells start to lose function prior to the onset of disease. TrialNet is currently evaluating the results of mechanistic studies to help answer some of those very questions,” Greenbaum added.

There were no serious adverse events, such as severe hypoglycemic events, reported during the trial. Infection was the most commonly reported event, but did not differ between the treatment and placebo groups (134 events treatment versus 120 events placebo).

In terms of future studies, Greenbaum highlighted the “Exploring the Immune Effects of Oral Insulin” study expected early next year, which aims to assess various regimens and dosage levels of oral insulin, and subsequent affect on immune response. “Two other prevention studies also underway are testing the drugs abatacept [Orencia] and teplizumab to see if they can delay or prevent disease progression prior to clinical diagnosis,” she noted.

Greenbaum also encouraged family members of people with type 1 diabetes to be screened for islet autoantibodies through the Pathway to Prevention study.

Click here for the American Association of Clinical Endocrinologists’ clinical practice guidelines for developing a diabetes mellitus comprehensive care plan.

The trial was supported by the Diabetes TrialNet Study Group.

Greenbaum and a co-author disclosed relevant relationships with Eli Lilly.

  • Reviewed by
    Robert Jasmer, MD Associate Clinical Professor of Medicine, University of California, San Francisco and Dorothy Caputo, MA, BSN, RN, Nurse Planner


last updated

Tagged with:

About author

Related Articles